These taken together suggests that MARCKS may be cooperating with or promoting NF-κB signaling, leading to more pronounced cancer aggressiveness as demonstrated by the poor outcomes in patients with upregulated NF-κB molecular signatures and increased phospho-MARCKS levels. Here, NFKB1 is linked to cancer.